[1] |
Williams IS,McVey A,Perera S,et al.Modern paradigms for prostate cancer detection and management[J].Med J Aust,2022,217(8): 424-433.DOI: 10.5694/mja2.51722.
|
[2] |
Achard V,Putora PM,Omlin A,et al.Metastatic prostate cancer:treatment options[J].Oncology,2022,100(1): 48-59.DOI:10.1159/000519861.
|
[3] |
Bochner E,Gold S,Raj GV.Emerging hormonal agents for the treatment of prostate cancer[J].Expert Opin Emerg Drugs,2022,27(3): 301-309.DOI: 10.1080/14728214.2022.2121390.
|
[4] |
Salciccia S,Frisenda M,Bevilacqua G,et al.Exosome analysis in prostate cancer: how they can improve biomarkers' performance[J].Curr Issues Mol Biol,2023,45(7): 6085-6096.DOI: 10.3390/cimb45070384.
|
[5] |
邹宇健,陈林.环状RNA 在前列腺癌中的研究进展[J].中华男科学杂志,2022,28(7): 649-655.DOI:10.13263/j.cnki.nja.2022.07.013.Zou YJ,Chen L.Research progress of cyclic RNA in prostate cancer[J].Natl J Androl,2022,28(7): 649-655.DOI: 10.13263/j.cnki.nja.2022.07.013.
|
[6] |
Yu W,Hurley J,Roberts D,et al.Exosome-based liquid biopsies in cancer: opportunities and challenges[J].Ann Oncol,2021,32(4):466-477.DOI: 10.1016/j.annonc.2021.01.074.
|
[7] |
Albino D,Falcione M,Uboldi V,et al.Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer[J].Commun Biol,2021,4(1): 119.DOI: 10.1038/s42003-020-01642-5.
|
[8] |
Johnstone RM,Adam M,Hammond JR,et al.Vesicle formation during reticulocyte maturation.Association of plasma membrane activities with released vesicles (exosomes)[J].J Biol Chem,1987,262(19): 9412-9420.
|
[9] |
Grimaldi AM,Salvatore M,Cavaliere C.Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: a systematic review of the literature[J].Prostate Cancer Prostatic Dis,2023,26(2): 228-239.DOI: 10.1038/s41391-022-00521-w.
|
[10] |
崔凌煦,红华,梁丹艳,等.经直肠超声造影联合血清外泌体对早期前列腺癌的诊断价值[J].中华实用诊断与治疗杂志,2022,36(11): 1145-1148.DOI: 10.13507/j.issn.1674-3474.2022.11.015.Cui LX,Hong H,Liang DY,et al.Value of transrectal contrastenhanced ultrasound combined with serum exosomes to the diagnosis of early prostate cancer[J].Chin J Pract Diagn Ther,2022,36(11):1145-1148.DOI: 10.13507/j.issn.1674-3474.2022.11.015.
|
[11] |
Li S,Zhao Y,Chen W,et al.Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer[J].J Cancer,2018,9(15):2659-2665.DOI: 10.7150/jca.25201.
|
[12] |
Sung BH,Ketova T,Hoshino D,et al.Directional cell movement through tissues is controlled by exosome secretion[J].Nat Commun,2015,6: 7164.DOI: 10.1038/ncomms8164.
|
[13] |
Larson J,Ozen MO,Kohli M,et al.Systematic analysis of tissuederived and biofluid extracellular vesicle miRNAs associated with prostate cancer[J].Adv Biol,2023,7(7): e2200327.DOI: 10.1002/adbi.202200327.
|
[14] |
Urabe F,Yamamoto Y,Kimura T.miRNAs in prostate cancer:Intercellular and extracellular communications[J].Int J Urol,2022,29(12): 1429-1438.DOI: 10.1111/iju.15043.
|
[15] |
田野,阿不都米吉提·阿不都克力木,王鹏,等.肿瘤相关巨噬细胞极化状态对前列腺癌干细胞自我更新能力和血管生成拟态的影响[J].吉林大学学报(医学版),2022,48(2): 374-382.DOI:10.13481/j.1671-587X.20220214.Tian Y,AbuduKelimu A,Wang P,et al.Effects of tumor-associated macrophage polarization status on self-renewal capacity and angiogenic mimicry of prostate cancer stem cells[J].J Jilin Univ (Med Ed),2022,48(2): 374-382.DOI: 10.13481/j.1671-587X.20220214.
|
[16] |
王雅轩.血管生成及干性特征相关标志物在前列腺癌中的研究进展[J].中华男科学杂志,2023,29(10): 944-948.DOI: 10.13263/j.cnki.nja.2023.10.014.Wang YX.Progress of angiogenesis and stemness characterizationrelated markers in prostate cancer[J].Natl J Androl,2023,29(10):944-948.DOI: 10.13263/j.cnki.nja.2023.10.014.
|
[17] |
梁博,刘军,姜明东,等.人脐间充质干细胞外泌体通过miR-126-3p 抑制前列腺癌生长的相关研究[J].中国性科学,2022,31(2): 16-20.DOI: 10.3969/j.issn.1672-1993.2022.02.005.Liang B,Liu J,Jiang MD,et al.Correlative study of human umbilical cord mesenchymal stem cell exosomes inhibiting prostate cancer growth via miR-126-3p[J].Chin J Hum Sex,2022,31(2): 16-20.DOI: 10.3969/j.issn.1672-1993.2022.02.005.
|
[18] |
Wu M,Wang G,Hu W,et al.Emerging roles and therapeutic value of exosomes in cancer metastasis[J].Mol Cancer,2019,18(1): 53.DOI:10.1186/s12943-019-0964-8.
|
[19] |
Bao L,You B,Shi S,et al.Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10[J].Oncogene,2018,37(21): 2873-2889.DOI: 10.1038/s41388-018-0183-6.
|
[20] |
张清元,刘敏,陆江婷,等.ABCC4 基因表达对前列腺癌免疫微环境的影响[J].广西医科大学学报,2023,40(2):245-253.DOI:10.16190/j.cnki.45-1211/r.2023.02.010.Zhang QY,Liu M,Lu JT,et al.Effect of ABCC4 gene expression on the immune microenvironment of prostate cancer[J].J Guangxi Med Univ,2023,40(2):245-253.DOI:10.16190/j.cnki.45-1211/r.2023.02.010.
|
[21] |
邵波,万水,田申,等.基于细胞焦亡基因前列腺癌预后模型的构建及肿瘤微环境分析[J].癌症进展,2024,22(2): 176-182.DOI:10.11877/j.issn.1672-1535.2024.22.02.15.Shao B,Wan S,Tian S,et al.Construction of a prognostic model of prostate cancer based on pyroptosis gene and analysis of tumor microenvironment[J].Oncol Prog,2024,22(2): 176-182.DOI:10.11877/j.issn.1672-1535.2024.22.02.15.
|
[22] |
Chowdhury R,Webber JP,Gurney M,et al.Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and proinvasive myofibroblasts[J].Oncotarget,2015,6(2): 715-731.DOI:10.18632/oncotarget.2711.
|
[23] |
Hsu YL,Hung JY,Chang WA,et al.Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1[J].Oncogene,2017,36(34): 4929-4942.DOI: 10.1038/onc.2017.105.
|
[24] |
叶芸.外泌体介导miR-141 调控前列腺癌骨转移微环境的分子机制[D].西安,中国人民解放军空军军医大学,2018.Ye Y.Molecular mechanism of exosomes mediating mir-141 regulating microenvironment of prostate cancer bone metastasis[D].Xian,Air Forco Medical University,2018.
|
[25] |
郑乃盛,汪婷婷,袁向亮,等.肿瘤相关巨噬细胞来源外泌体激活IFN 通路促进胃癌细胞免疫逃逸[J].现代免疫学,2021,41(1):24-31.DOI: 1001-2478(2021)01-0024-08.Zheng NS,Wang TT,Yuan XL,et al.Tumor-associated macrophagesderived exosomes promote immune escape of gastric cancer cells via IFN pathway[J].Curr Immunol,2021,41(1): 24-31.DOI:1001-2478(2021)01-0024-08.
|
[26] |
Lundholm M,Schröder M,Nagaeva O,et al.Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion[J].PLoS One,2014,9(9): e108925.DOI: 10.1371/journal.pone.0108925.
|
[27] |
Salimu J,Webber J,Gurney M,et al.Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes[J].J Extracell Vesicles,2017,6(1): 1368823.DOI:10.1080/20013078.2017.1368823.
|
[28] |
Li W,Dong Y,Wang KJ,et al.Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer[J].Neoplasma,2020,67(6): 1314-1318.DOI: 10.4149/neo_2020_191130N1234.
|
[29] |
Duca RB,Massillo C,Dalton GN,et al.miR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis[J].Am J Cancer Res,2021,11(6): 2802-2820.
|
[30] |
Zhou C,Chen Y,He X,et al.Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer[J].Onco Targets Ther,2020,13: 11595-11606.DOI: 10.2147/OTT.S272869.
|
[31] |
Wang J,Ni J,Beretov J,et al.Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer[J].Crit Rev Oncol Hematol,2020,145:102860.DOI: 10.1016/j.critrevonc.2019.102860.
|
[32] |
Foj L,Ferrer F,Serra M,et al.Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis[J].Prostate,2017,77(6): 573-583.DOI: 10.1002/pros.23295.
|
[33] |
Holdmann J,Markert L,Klinger C,et al.microRNAs from urinary exosomes as alternative biomarkers in the differentiation of benign and malignant prostate diseases[J].J Circ Biomark,2022,11: 5-13.DOI: 10.33393/jcb.2022.2317.
|
[34] |
李腊秀,马越云,李卓,等.尿液exosomal miR-375 在前列腺癌诊断中的价值初探[J].中华检验医学杂志,2017,40(4): 273-277.DOI: 10.3760/cma.j.issn.1009-9158.2017.04.012.Li (L/X)X,Ma YY,Li Z,et al.Exosome-encapsulated miR-375 in urine as a non-invasive biomarker for prostate cancer diagnosis[J].Chin J Lab Med,2017,40(4): 273-277.DOI: 10.3760/cma.j.issn.1009-9158.2017.04.012.
|
[35] |
Shin S,Park YH,Jung SH,et al.Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J].NPJ Genom Med,2021,6(1): 45.DOI: 10.1038/s41525-021-00212-w.
|
[36] |
Kim MY,Shin H,Moon HW,et al.Urinary exosomal microRNA profiling in intermediate-risk prostate cancer[J].Sci Rep,2021,11(1):7355.DOI: 10.1038/s41598-021-86785-z.
|
[37] |
赵晓东,陈颖琦,刘喆,等.外泌体作为新型诊断标志物在前列腺癌中的研究进展[J].中华男科学杂志,2022,28(12): 1123-1128.DOI: 10.13263/j.cnki.nja.2022.12.011.Zhao XD,Chen YQ,Liu Z,et al.Exosomes in the diagnosis of prostate cancer: Advances in studies[J].Natl J Androl,2022,28(12):1123-1128.DOI: 10.13263/j.cnki.nja.2022.12.011.
|
[38] |
Barceló M,Castells M,Bassas L,et al.Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis[J].Sci Rep,2019,9(1): 13772.DOI: 10.1038/s41598-019-50172-6.
|
[39] |
Ghosh S,Garg S,Ghosh S.Cell-derived exosome therapy: a novel approach to treat post-traumatic brain injury mediated neural injury[J].ACS Chem Neurosci,2020,11(14): 2045-2047.DOI:10.1021/acschemneuro.0c00368.
|
[40] |
Saari H,Lázaro-Ibáñez E,Viitala T,et al.Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells[J].J Control Release,2015,220(Pt B): 727-737.DOI: 10.1016/j.jconrel.2015.09.031.
|
[41] |
吕立国,吴巧玲,黄娟,等.含蜂毒肽的前列腺癌外泌体制备及体外评价[J].中国药理学通报,2023,39(2): 392-399.DOI:10.12360/CPB202203104.Lv LG,Wu QL,Huang J,et al.Preparation and in vitro evaluation of exosomes containing bee venom peptide for prostate cancer[J].Chin J Pharmacol,2023,39(2): 392-399.DOI:10.12360/CPB202203104.
|
[42] |
Kyuno D,Zhao K,Bauer N,et al.Therapeutic targeting cancerinitiating cell markers by exosome miRNA: efficacy and functional consequences exemplified for claudin7 and EpCAM[J].Transl Oncol,2019,12(2): 191-199.DOI: 10.1016/j.tranon.2018.08.021.
|
[43] |
杜秋伶,钟惟德.前列腺癌的药物治疗研究进展及展望[J].中华实验外科杂志,2023,40(12): 2429-2436.DOI: 10.3760/cma.j.cn421213-20230416-01120.Du QL,Zhong WD.Research progress and prospects of drug treatment for prostate cancer[J].Chin J Exp Surg,2023,40(12):2429-2436.DOI: 10.3760/cma.j.cn421213-20230416-01120.
|